<?xml version="1.0" encoding="UTF-8"?>
<p>Due to the similar active‐site architecture of the 3Cl protease in coronaviruses and enteroviruses, Zhang et al designed peptidomimetic α‐ketoamides as proper 3Cl protease inhibitors to attain the broad‐spectrum anti‐viral drugs. They introduced a compound (11r) expecting to exhibit excellent anti‐viral activity against SARS‐CoV‐2 (Li &amp; De Clercq, 
 <xref rid="tbed13734-bib-0042" ref-type="ref">2020</xref>; Zhang, Lin, et al., 
 <xref rid="tbed13734-bib-0101" ref-type="ref">2020</xref>).
</p>
